AstraZeneca, Health Economics and Outcomes Research, Gaithersburg, MD, USA.
IQVIA, Real-World Insights, Saint-Ouen, France.
J Infect. 2018 Jul;77(1):9-17. doi: 10.1016/j.jinf.2018.04.002. Epub 2018 May 6.
To assess real-world treatment patterns and clinical outcomes associated with initial antibiotic therapy (IAT, antibiotics received ≤ 48 h post-initiation of antibiotic therapy), including level of IAT failure, and potential risk factors for IAT failure in healthcare-associated infections.
Data were obtained from medical records of adult patients hospitalized with healthcare-associated pneumonia (HCAP) and nosocomial pneumonia (NP), including ventilator-associated pneumonia, from 1 July 2013 to 30 June 2014 in Brazil, France, Italy, Russia and Spain during the retrospective, observational study, RECOMMEND (NCT02364284; D4280R00005). Potential risk factors for IAT failure were explored using logistic regression analyses.
Mean (standard deviation) age and Deyo-Charlson Comorbidity Score were 66.0 (16.2) years and 2.4 (2.4), respectively (N = 451). Most patients (62.5%) received monotherapy. Mean (standard deviation) duration of IAT was 8.8 (7.2) days. Multidrug-resistant (MDR) pathogens were identified in 52.4% of patients with ≥ 1 pathogen isolated (154/294). IAT failure was recorded in 72.5% of patients and was significantly associated with isolation of a MDR pathogen and country using multivariate analyses.
Real-world data demonstrate the burden of HCAP/NP, with high rates of IAT failure. The association of IAT failure with MDR pathogens highlights the urgent need to understand and account for local prevalence of MDR pathogens when selecting IAT for the management of HCAP/NP.
评估与初始抗生素治疗(IAT,抗生素治疗开始后≤48 小时内接受的抗生素)相关的真实世界治疗模式和临床结局,包括 IAT 失败率,以及医疗保健相关性感染中 IAT 失败的潜在危险因素。
数据来自 2013 年 7 月 1 日至 2014 年 6 月 30 日期间在巴西、法国、意大利、俄罗斯和西班牙进行的回顾性观察性研究 RECOMMEND(NCT02364284;D4280R00005)中因医疗保健相关性肺炎(HCAP)和医院获得性肺炎(NP)住院的成年患者的病历,包括呼吸机相关性肺炎。使用逻辑回归分析探讨 IAT 失败的潜在危险因素。
平均(标准差)年龄和 Deyo-Charlson 合并症评分分别为 66.0(16.2)岁和 2.4(2.4)(N=451)。大多数患者(62.5%)接受单药治疗。IAT 的平均(标准差)持续时间为 8.8(7.2)天。≥1 种病原体分离的患者中,有 52.4%(154/294)发现了耐多药病原体。在多变量分析中,72.5%的患者记录了 IAT 失败,与分离出耐多药病原体和国家显著相关。
真实世界数据表明 HCAP/NP 的负担沉重,IAT 失败率很高。IAT 失败与耐多药病原体的关联突出表明,在选择 IAT 治疗 HCAP/NP 时,迫切需要了解和考虑当地耐多药病原体的流行情况。